The estimated Net Worth of Amit Kumar is at least 2.32 百万$ dollars as of 7 June 2024. Dr Kumar owns over 25,000 units of Anixa Biosciences stock worth over 1,597,298$ and over the last 9 years he sold ANIX stock worth over 0$. In addition, he makes 720,865$ as Chairman、 Pres & CEO at Anixa Biosciences.
Dr has made over 26 trades of the Anixa Biosciences stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of ANIX stock worth 60,250$ on 7 June 2024.
The largest trade he's ever made was exercising 640,000 units of Anixa Biosciences stock on 15 September 2022 worth over 1,651,200$. On average, Dr trades about 26,322 units every 88 days since 2015. As of 7 June 2024 he still owns at least 516,925 units of Anixa Biosciences stock.
You can see the complete history of Dr Kumar stock trades at the bottom of the page.
Dr. Amit Kumar Ph.D. is the Chairman, Pres & CEO at Anixa Biosciences.
As the Chairman、 Pres & CEO of Anixa Biosciences, the total compensation of Dr D at Anixa Biosciences is 720,865$. There are no executives at Anixa Biosciences getting paid more.
Dr D is 57, he's been the Chairman、 Pres & CEO of Anixa Biosciences since . There are 5 older and 5 younger executives at Anixa Biosciences. The oldest executive at Anixa Biosciences, Inc. is Lewis Titterton, 75, who is the Lead Independent Director.
Amit's mailing address filed with the SEC is C/O ANIXA BIOSCIENCES, INC., 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE,, CA, 95118.
Over the last 6 years, insiders at Anixa Biosciences have traded over 0$ worth of Anixa Biosciences stock and bought 834,156 units worth 2,822,805$ . The most active insiders traders include Amit Kumar、Lewis H Jr Titterton、Arnold M Baskies. On average, Anixa Biosciences executives and independent directors trade stock every 31 days with the average trade being worth of 78,894$. The most recent stock trade was executed by Lewis H Jr Titterton on 30 July 2024, trading 27,226 units of ANIX stock currently worth 84,128$.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Anixa Biosciences executives and other stock owners filed with the SEC include: